Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Crows have brains ‘in the fast lane’
The birds accurately complete decision-making tasks twice as fast as primates, although their endbrains look considerably different.
Crows have brains ‘in the fast lane’
The birds accurately complete decision-making tasks twice as fast as primates, although their endbrains look considerably different.
Prevalence of profound autism declines with new definition
The updated, more precise definition used in a CDC study includes adaptive scores.
Prevalence of profound autism declines with new definition
The updated, more precise definition used in a CDC study includes adaptive scores.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.